Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Catalent Biologics announced a long-term strategic agreement for the development and manufacturing of Zolgensma®, an AveXis gene therapy treatment for spinal muscular atrophy.
read more
Wednesday, October 19, 2016
Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced that it is to provide fill-finish production services for the commercial supply ...
read more
Wednesday, September 26, 2018
GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of proprietary APIs for its Parkinson’s disease therapies
read more
Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
read more
Friday, November 22, 2019
Catalent has entered into a long-term commercial supply agreement with BeiGene.
read more
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products...
read more
Catalent Pharma Solutions, has reached a commercial supply agreement with Palatin Technologies, Inc., to support the global commercial product launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (...
read more
Wednesday, October 27, 2021
Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announced a $230 million expansion project to add three ...
read more
Monday, February 24, 2020
Catalent announced Senior Vice President & Chief Financial Officer, Wetteny Joseph, has been inducted as a member of the Executive Leadership Council (ELC).
read more
Catalent announced the company will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222.
read more
Catalent and BrainStorm an agreement for the manufacture of NurOwn, BrainStorm’s autologous cellular therapy being investigated for the treatment of ALS.
read more
Catalent has signed an agreement with Cybin to apply Catalent’s proprietary Zydis ODT technology for the delivery of Cybin’s novel deuterated tryptamine.
read more
Catalent, Inc. (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the pricing of its initial public offering of 42,500,000 shares of...
read more
Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19.
read more
Catalent announced an expanded partnership with Janssen Pharmaceutica and Janssen Pharmaceuticals whereby Catalent will increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing ...
read more